| Cas No.: | 1392312-45-6 |
| Chemical Name: | BMS-955176 free base |
| Synonyms: | BMS-955176(free base);GSK3532795 |
| SMILES: | C1C(C(=O)O)=CC=C(C2=CC[C@]3(C)[C@@]4([H])CC[C@]5([H])[C@@]6([H])[C@H](C(C)=C)CC[C@]6(NCCN6CCS(=O)(=O)CC6)CC[C@@]5(C)[C@]4(C)CC[C@@]3([H])C2(C)C)C=1 |
| Formula: | C42H62N2O4S |
| M.Wt: | 691.028 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | BMS-955176 (GSK-3532795) is a second-generation HIV-1 maturation inhibitor that exhibits potent activity (EC50=3.9±3.4 nM) against a library (n=87) of gag/pr recombinant viruses; exhibits median EC50 of 21 nM toward a library of subtype B clinical isolates assayed in PBMCs; inhibits HIV-1 protease cleavage at the CA/SP1 junction within Gag in VLPs and in HIV-1-infected cells, and binds reversibly and with high affinity to assembled Gag in purified HIV-1 VLPs; has a greatly improved preclinical profile compared to that of Bevirimat. HIV Infection Phase 2 Clinical |

To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
